Text

Korelasi Kadar Interleukin 3 dan eritropoietin dengan Hemoglobin Akibat Kemoterapi pada Pasien Kanker Paru

---

Chemotherapy result at lung cancer patient often be minimized by hematology imbalance during therapy period. Erythropoientin (EPO) and interleukin IL-3 were important for making red blood cell. White blood cell and platelets cell. This research was done to se whether EPO and IL-3 at lung cancer patient serum could be prediction factor for anemia caused by chemotherapy. The objective of this study was to evaluate the hematology toxicities of carboplatin plus etoposide or paclitaxel as firs line therapy in patients with advanced non small cell lung cancer (NSCLC). We also looked for serum marker to detect anemia, due to chemotherapy. Thirty one patients with stage IIIB/IV NSCLC a performance status of 0-1 and no prior chemotherapy exposure were eligible. Patients received Carboplatin AUC-5 day 1+ etoposide 100 mg/m2 day 1-3 or carboplatin AUC-5+ paclitaxel 175 mg/m2 at three weekly cycle. Leucocyte, hemoglobin (HB) and thrombocyte were count before and every week in during chemotherapy. To investigate EPO and IL-3 level, 3 ml peripheral bloods of patients were taken to count IL-3 and 2 ml for EPO level by ELISA quantitative methods. A median of chemotherapy was 4,5 cycles (range 2-6). Twenty five (80,6%) patients had anemia Mostly hemotology toxicities were mild. The most common toxicity was founded at week 2 in first cycle of chemotherapy. We have founded correlation between anemia due to chemotherapy with EPO and IL 3. These results demonstrate that this regimen is an active and tolerable treatment for patients with and tolerable treatment for patients with advanced NSCLC. EPO and/or IL 3 as serum marker of hematopoietic imbalance for patients who will take chemotherapy were not strong enough.

---

Ketersediaan

Informasi Detail

Judul Seri

-

No. Panggil

Jurnal Respirologi Indonesia, 28(4):190-196

Penerbit

Jakarta : Perhimpunan Dokter Paru Indonesia., 2008

Deskripsi Fisik

6p.

Bahasa

ISBN/ISSN

0853-7704

Klasifikasi

-

Tipe Isi

-

Tipe Media

-

Tipe Pembawa

-

Edisi

-

Subjek

hemoglobins
drug therapy
lung neoplasms

Info Detail Spesifik

-

Pernyataan Tanggungjawab

-

Versi lain/terkait

Lampiran Berkas

Komentar

---

Anda harus masuk sebelum memberikan komentar